Alivus Life Sciences Q2 FY26 Concall Decoded: – “Margins on Steroids, Capex on Diet”
1. Opening Hook
When a pharma company rebrands itself, investors usually brace for a bitter aftertaste. But Alivus (formerly Glenmark Life Sciences) seems to have added a growth booster instead of a placebo. The company’s Q2 FY26 call had everything — solid numbers, cautious optimism, and a gentle hint of “don’t worry, we’re not spending recklessly.” From AI-fueled industry chatter to CDMO dreams and cash-rich declarations, the management kept things spicy without overdosing on jargon. Read on — things get funnier (and sharper) as we unpack how Alivus plans to turn its cash pile into future chemistry. 💊
2. At a Glance
Revenue up 16%: CFO insists it’s “organic growth,” not Excel inflation.
EBITDA surged 36%: Clearly, efficiency meds are working.
EBITDA Margin 33%: Big pharma energy in mid-cap clothes.
Dr. Yasir Rawjee (CEO): “Non-GPL business grew 39.7%, GPL to rebound in H2.” (Translation: One leg sprinting, the other still tying its shoes.) 😏
“Gross margin up 210 bps, EBITDA up 480 bps – driven by product mix and rationalized costs.” (Translation: Finally, a quarter where costs behaved like obedient interns.)
“CDMO looks soft but will rebound in H2 as new projects kick in.” (Translation: ‘Trust me, bro’ — every CDMO ever.)
“Pipeline strong with 586 DMF/CEP filings; 26 high-potent APIs in play worth $66 bn market.” (Translation: We’re sitting on enough molecules to start a periodic table of our own.)
CFO Tushar Mistry: “We remain net debt-free with ₹653 cr cash.” (Translation: We could buy a small biotech just for fun.)
“Capex guidance ₹600 cr, but actual spend slower.” (Translation: Delays are now a corporate virtue.)
“Margins around 30% sustainable even without PLI benefits.” (Translation: No government subsidy, still flexing.) 💪
